Topical sirolimus: Difference between compounded preparations and commercial oral solution
| Autor: | Lars Brichta, James G. Carver, Cynthia Marie Carver DeKlotz |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Administration Topical Dermatology Ointments 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Oral administration medicine Humans cardiovascular diseases Dermatologic disorders Sirolimus Compounded preparations business.industry Treatment options equipment and supplies surgical procedures operative Compounding 030220 oncology & carcinogenesis Pediatrics Perinatology and Child Health cardiovascular system Topical Sirolimus business Gels Immunosuppressive Agents medicine.drug |
| Zdroj: | Pediatric Dermatology. 38:967-969 |
| ISSN: | 1525-1470 0736-8046 |
| Popis: | Topical sirolimus has become a crucial treatment option for many dermatologic disorders. Because an FDA-approved topical formulation is not commercially available, sirolimus creams, ointments, and gels are professionally prepared by compounding pharmacies. Also, the topical use of a commercially available sirolimus solution approved for oral administration is described regularly. To better guide providers in their decision-making when topical sirolimus is being considered, this article highlights the substantial pharmaceutical and clinical differences between commercial oral solution and compounded preparations specifically designed for topical therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text